SecBot SecBot
8-K ·Filed Nov 5, 2026

TENX

TENAX THERAPEUTICS, INC.
NEUTRAL
Impact 5/10
Horizonweeks Processed11d 20h ago SEC0001193125-26-448517
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The FDA Type C meeting outcome and LEVEL-2 enrollment restart timeline are the next catalysts. The enrichment strategy is hypothesis-generating and may not be accepted by regulators; monitor for protocol publication and FDA feedback in Q1 2027.

DirectionNeutral
Confidencehigh
Horizonweeks

levosimendan

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3
Time to market
If LEVEL Phase 3 data is positive (Aug 2026), Tenax would need to complete a second registrational study (LEVEL-2) and file an NDA. Realistic best-case US approval would be 2028-2029, assuming positive results and a standard FDA review cycle.
Next catalyst
None dated

What to watchThe Phase 3 LEVEL topline readout in August 2026 is a make-or-break binary catalyst. Positive data could unlock a ~$2B+ market opportunity as the first approved therapy for PH-HFpEF, while a miss would likely devastate the stock. With a strong cash runway (~$118.8M through Q1 2028), no near-term dilution risk exists. This is a pure binary options-style biotech setup, size accordingly.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.63
T+0 close · Nov 5, 2026 · via day close
Latest settled
−1.23%
T+5 · $1.61
Vs SPY
−4.52%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $1.63entry
  2. T+1 · 11d ago +3.68%α +3.37% · $1.69
  3. T+5 · 5d ago −1.23%α −4.52% · $1.61
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

The primary news is the completion of statistical analyses from the failed Phase 3 LEVEL trial, yielding a predictive enrichment strategy being applied to the amended LEVEL-2 protocol, and a granted Type C meeting with the FDA. Cash runway extended through fiscal 2028.

Key Financial Metrics

Revenue
$0.00
est $0.00

Key Facts

  • Cash and cash equivalents of $113.7M as of September 30, 2026; cash runway through fiscal 2028
  • Phase 3 LEVEL trial did not meet primary endpoint; post hoc analysis identified enrichment criteria for LEVEL-2
  • LEVEL-2 enrollment temporarily paused for protocol amendment to enrich for more symptomatic patients
  • FDA granted a Type C meeting to discuss overall development of levosimendan in PH-HFpEF
  • R&D expenses $12.1M in Q3 2026 vs $10.3M in Q3 2025
  • SG&A expenses $5.7M in Q3 2026 vs $6.5M in Q3 2025

Financial Impact

Q3 net loss $16.7M; cash burn $4.3M in Q3; cash runway extended through fiscal 2028

net losscash positionR&D expenses

Risk Factors

  • LEVEL trial failed primary endpoint; subgroup/post hoc analyses may not be confirmed in LEVEL-2
  • FDA may disagree with revised development plan or require additional trials
  • Enrichment criteria may slow LEVEL-2 enrollment and reduce commercial opportunity
  • Potential need for dilutive financing if cash runway assumptions change after FDA meeting

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
69% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-448517
Document: d33477d8k.htm0001193125-26-448517
Document: 0001193125-26-448517-index-headers.html0001193125-26-448517
Document: 0001193125-26-448517-index.html0001193125-26-448517
Document: 0001193125-26-448517.txt0001193125-26-448517
8-K Data (Synthetic)0001193125-26-448517

Track record

30 reports on TENX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.48 Now $1.48 +0.00% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 4/10 Entry $1.52 Now $1.48 −2.63% settles Dec 16
  3. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.52 Now $1.48 +2.63% settles Dec 16
  4. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.52 Now $1.48 +2.63% settles Dec 15
  5. Nov 16, 2026today SC 13G Neutral 3/10 Entry $1.60 Now $1.48 −7.51% settles Dec 15
  6. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $1.62 Now $1.48 +8.64% settles Dec 15
  7. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $1.61 Now $1.48 −8.07% settles Dec 11
  8. Nov 5, 202611d ago 8-K Neutral 5/10 Viewing Entry $1.63 Now $1.48 −9.20% settles Dec 4
  9. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $1.88 Now $1.48 −21.28% settles Nov 25
  10. Oct 15, 20264w ago SC 13G/A Neutral 3/10 Entry $1.36 to $1.62 Now $1.48 +8.82% ▲ +19.12% +20.28% vs SPY
Showing 10 of 30

US Market Status

Market Closed · Opens in 6h

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026